← Back to headlines
Neurocrine to Acquire Soleno in $2.9 Billion Deal
Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a transaction valued at approximately $2.9 billion.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
